Can I Take Reishi Mushroom with Leqvio (Inclisiran)?

How Inclisiran Works and Why It Matters for Supplement Interactions

Inclisiran is a first-in-class small interfering RNA (siRNA) that silences the gene encoding PCSK9 in hepatocytes. By reducing PCSK9 protein production, it increases LDL receptor recycling on liver cell surfaces and pulls more LDL-C out of the bloodstream. The FDA approved it in December 2021 for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statins [1].

A Unique Metabolic Pathway

What makes inclisiran different from most cholesterol drugs is its metabolism. Standard small-molecule drugs like statins pass through cytochrome P450 enzymes in the liver. Inclisiran does not. Once the siRNA reaches the hepatocyte, intracellular nucleases break it down into inactive nucleotide fragments [2]. This means the typical CYP-mediated drug-supplement interactions that complicate statin therapy are not relevant here.

Clinical Efficacy Benchmarks

In the ORION-10 trial (N=1,561), inclisiran 284 mg reduced LDL-C by 52.3% versus placebo at day 510 (P<0.001) [3]. The ORION-11 trial (N=1,617) showed a 49.9% reduction over the same period [3]. These numbers set the bar: any supplement interaction worth worrying about would need to meaningfully blunt that effect or introduce a new safety signal.

What Reishi Mushroom Does in the Body

Reishi (Ganoderma lucidum) has been used in East Asian traditional medicine for over 2,000 years. Modern research focuses on its triterpenes (ganoderic acids), polysaccharides (beta-glucans), and small peptides. Each compound class acts through a different mechanism.

Triterpenes and Lipid Metabolism

Ganoderic acids have shown modest lipid-lowering activity in preclinical models. A 2015 study in BMC Complementary and Alternative Medicine reported that Ganoderma lucidum polysaccharides reduced total cholesterol and triglycerides in hyperlipidemic rats, with proposed mechanisms including HMG-CoA reductase inhibition and enhanced bile acid excretion [4]. Human data is sparse. A Cochrane review (Klupp et al., 2015) of five randomized controlled trials (N=398) found no statistically significant effect of Ganoderma lucidum on total cholesterol, LDL-C, HDL-C, or triglycerides in humans [5].

Immune Modulation

Reishi beta-glucans activate dendritic cells and macrophages via Dectin-1 and complement receptor 3 (CR3) signaling. A 2003 study in Immunology Letters showed reishi polysaccharides promoted dendritic cell maturation and Th1 cytokine production in vitro [6]. This immune-stimulating capacity is the reason reishi is marketed as an immune support supplement, but it also raises a theoretical question: could immune activation at the hepatocyte level affect siRNA uptake or processing? No study has tested this directly.

Antiplatelet Activity

This is the most clinically relevant pharmacodynamic property. A 2004 study in Journal of Ethnopharmacology demonstrated that Ganoderma lucidum inhibited platelet aggregation in human blood samples in a dose-dependent manner, with ganoderic acid S identified as the primary active compound [7]. Platelet inhibition matters because many ASCVD patients receiving Leqvio are already on aspirin, clopidogrel, or both.

Assessing the Interaction Risk: Pharmacokinetic Analysis

The pharmacokinetic interaction risk between reishi and inclisiran is low. Here is why that assessment holds up under scrutiny.

CYP450 Independence

Inclisiran's prescribing information explicitly states it is not a substrate, inhibitor, or inducer of CYP450 enzymes or major drug transporters (P-glycoprotein, OATP1B1, OATP1B3) [2]. Reishi triterpenes have demonstrated CYP3A4, CYP2E1, and CYP1A2 inhibition in vitro [8], but these findings are irrelevant to a drug that never touches the CYP system.

Hepatic Uptake Pathway

Inclisiran uses an N-acetylgalactosamine (GalNAc) conjugate to bind the asialoglycoprotein receptor (ASGPR) on hepatocytes. No published evidence suggests reishi compounds compete for ASGPR binding or alter its expression. The receptor is highly abundant on liver cells (approximately 500,000 copies per hepatocyte), making competitive inhibition by a dietary supplement implausible at standard doses [9].

Protein Binding

Inclisiran is 87% protein-bound in plasma [2]. Reishi compounds are not known to displace highly protein-bound drugs. Even if displacement occurred, inclisiran's intracellular mechanism of action means transient increases in free drug would have minimal clinical impact.

Assessing the Interaction Risk: Pharmacodynamic Analysis

The pharmacodynamic side of the equation deserves more attention. Two mechanisms warrant discussion.

Bleeding Risk Amplification

Patients with ASCVD frequently take dual antiplatelet therapy (DAPT), typically aspirin plus a P2Y12 inhibitor. Reishi's antiplatelet activity, documented in both in vitro and limited human data, could stack on top of DAPT to increase bleeding risk [7]. No case reports of reishi-induced bleeding in patients on inclisiran specifically have been published. But the absence of reports does not equal safety, particularly given that Leqvio has been on the market only since 2021.

A practical framework: if you are on Leqvio alone without anticoagulants or antiplatelet agents, reishi's bleeding risk is a minor concern. If you take Leqvio alongside aspirin, clopidogrel, rivaroxaban, or apixaban, the additive antiplatelet effect of reishi becomes clinically relevant and should be discussed with your cardiologist.

Immune Modulation and Injection-Site Biology

Inclisiran is injected subcutaneously. The injection triggers a local immune response that includes macrophage recruitment and minor inflammation at the injection site (reported in 8.2% of patients in ORION-10 versus 1.8% placebo) [3]. Reishi's activation of innate immune cells could theoretically amplify injection-site reactions, though no data supports or refutes this hypothesis.

One consideration for immunocompromised patients: if you take reishi for its immune-stimulating properties while also on immunosuppressive medications post-transplant, the interaction calculus changes significantly. Transplant recipients are generally excluded from inclisiran trials, so evidence is limited in this population [10].

What the Databases Say

Neither the Natural Medicines database nor the FDA's adverse event reporting system (FAERS) lists a specific interaction between Ganoderma lucidum and inclisiran as of May 2026. The Natural Medicines database classifies reishi interactions primarily around anticoagulant and antiplatelet potentiation, immunosuppressant interference, and antihypertensive additivity [11].

Grading the Evidence

The Natural Medicines database rates the reishi-antiplatelet interaction as "moderate" severity with "fair" evidence quality. This grading reflects a pattern common across supplement-drug interaction data: mechanistic plausibility is strong, but controlled human trials confirming the interaction are absent.

What FAERS Data Shows

A search of FDA FAERS for inclisiran adverse events through Q1 2026 returns no reports mentioning Ganoderma, reishi, or mushroom supplements. This is expected. FAERS captures voluntarily reported events, and supplement co-use is underreported. A 2023 survey in JAMA Network Open estimated that only 33% of patients disclose supplement use to their prescribers [12].

Monitoring Recommendations if You Take Both

If you and your clinician decide to continue reishi alongside Leqvio, structured monitoring reduces risk.

Lipid Panel Timing

Check a standard lipid panel (LDL-C, HDL-C, triglycerides, total cholesterol) at baseline before your first Leqvio dose, 90 days after the initial injection, and then every 6 months aligned with your injection schedule [2]. Compare your LDL-C reduction against the expected 50 to 52% from ORION trial data. A substantially smaller reduction warrants investigation, though attributing it to reishi specifically would require stopping the supplement and rechecking.

Bleeding Surveillance

If you take antiplatelet or anticoagulant drugs concurrently, request a CBC with platelet count and consider adding a platelet function assay (such as VerifyNow P2Y12 or light transmission aggregometry) at your next cardiology visit. Report any unusual bruising, prolonged bleeding from cuts, blood in stool, or dark urine immediately [7].

Liver Function

Both inclisiran and reishi are processed in the liver. While inclisiran showed no hepatotoxicity signals in ORION trials (ALT/AST elevations were similar to placebo at 1.6% versus 1.3%) [3], reishi has rare case reports of hepatotoxicity, including one case of fatal fulminant hepatitis attributed to powdered Ganoderma lucidum in a 47-year-old woman published in the World Journal of Hepatology in 2019 [13]. Check hepatic function tests (ALT, AST, total bilirubin) at baseline and 6 months.

Dose Separation

No evidence supports a specific dose-separation window between reishi and inclisiran. Since Leqvio is injected every 6 months and reishi is taken daily, temporal separation is not practical or pharmacologically meaningful. If you take reishi daily, simply continue your routine on injection days.

Reishi's Effect on Cholesterol: Does It Help or Hinder Leqvio?

Some patients take reishi specifically for its purported lipid-lowering effects, hoping for additive benefit alongside Leqvio. The evidence does not support this expectation.

Human Trial Data

The 2015 Cochrane review by Klupp et al. Analyzed five RCTs with 398 total participants and found no statistically significant reduction in any lipid parameter from Ganoderma lucidum supplementation compared to placebo [5]. The pooled mean difference for LDL-C was -0.04 mmol/L (95% CI: -0.20 to 0.12), a clinically meaningless effect [5].

Theoretical Additivity

Even if reishi had a small lipid-lowering effect, the mechanism (HMG-CoA reductase inhibition, if confirmed in humans) would be independent of inclisiran's PCSK9 silencing pathway. There is no mechanistic reason to expect interference. Two agents working through different pathways typically produce additive, not antagonistic, effects on LDL-C.

Clinical Guidance from Professional Societies

The 2022 ACC Expert Consensus Decision Pathway for the role of nonstatin therapies positions inclisiran as a second-line injectable option after PCSK9 monoclonal antibodies (evolocumab, alirocumab) for patients not reaching LDL-C targets [14]. The document does not address botanical supplement co-use, reflecting the broader gap in cardiology guidelines around dietary supplement management.

Special Populations

Patients with Chronic Kidney Disease

Inclisiran does not require dose adjustment for mild-to-moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²) [2]. Reishi's renal safety profile is poorly characterized. If your eGFR falls below 60, discuss any supplement use, including reishi, with your nephrologist before continuing.

Older Adults

Patients over 65 made up 44% of ORION-10 participants, and no age-related differences in efficacy or safety were observed [3]. Older adults are more likely to take multiple medications, increasing the potential for pharmacodynamic stacking. A medication reconciliation that includes all supplements should occur at every injection visit.

Patients on Warfarin

Reishi has demonstrated both antiplatelet and mild anticoagulant activity in preclinical models [7]. Patients on warfarin should monitor INR more frequently (every 2 to 4 weeks rather than monthly) if they start or stop reishi, and should report any INR values above their therapeutic range immediately.